Browsing by Author "Bojic, Svetlana (55816098800)"

This study provides the first published detailed analysis of five loci polymorphisms as well as reports of two, three and five loci haplotype frequencies in the Serbian population in a sample of 1992 volunteer bone marrow donors recruited from different part of the country. Typing was performed by PCR SSO method combined with PCR SSP techniques to resolve ambiguities. In total, 16 HLA-A, 28 HLA-B, 14 HLA-C, 13 HLA-DRB1 and 5 HLA-DQB1 allelic groups were identified. The most frequent in allele groups are HLA-A*02 (29.5%), HLA-A*01 (14.2%), HLA-B*35 (13.1%), HLA-B*51 (12.8%), HLA-C*07 (24.8%), HLA-DRB1*11 (16.9%), HLA-DRB1*13 (13.2%), HLA-DQB1*03 (33.3%) and DQB1*05 (33.0%). The most frequent three- and five-loci haplotypes were A*01-B*08-DRB1*03 (5.9%) and A*02-B*18-DRB1*11 (1.9%), A*01-B*08-C*07-DRB1*03-DQB1*02 (6.6%) followed by A*02-B*18-C*07-DRB1*11-DQB1*03 (2.5%), then A*33-B*14-C*08-DRB1*01-DQB1*05 and A*02-B*35-C*04-DRB1*16-DQB1*05 (2.2% both), respectively. The results of cluster analysis showed that the Serbian population is closely related to the populations living in central Balkan and neighboring European regions. The level of allelic diversity found in this study are relevant to facilitate searching for unrelated matched donor and provide a healthy control population from our region that should be useful in the future disease association study. © 2013 American Society for Histocompatibility and Immunogenetics.

This study provides the first published detailed analysis of five loci polymorphisms as well as reports of two, three and five loci haplotype frequencies in the Serbian population in a sample of 1992 volunteer bone marrow donors recruited from different part of the country. Typing was performed by PCR SSO method combined with PCR SSP techniques to resolve ambiguities. In total, 16 HLA-A, 28 HLA-B, 14 HLA-C, 13 HLA-DRB1 and 5 HLA-DQB1 allelic groups were identified. The most frequent in allele groups are HLA-A*02 (29.5%), HLA-A*01 (14.2%), HLA-B*35 (13.1%), HLA-B*51 (12.8%), HLA-C*07 (24.8%), HLA-DRB1*11 (16.9%), HLA-DRB1*13 (13.2%), HLA-DQB1*03 (33.3%) and DQB1*05 (33.0%). The most frequent three- and five-loci haplotypes were A*01-B*08-DRB1*03 (5.9%) and A*02-B*18-DRB1*11 (1.9%), A*01-B*08-C*07-DRB1*03-DQB1*02 (6.6%) followed by A*02-B*18-C*07-DRB1*11-DQB1*03 (2.5%), then A*33-B*14-C*08-DRB1*01-DQB1*05 and A*02-B*35-C*04-DRB1*16-DQB1*05 (2.2% both), respectively. The results of cluster analysis showed that the Serbian population is closely related to the populations living in central Balkan and neighboring European regions. The level of allelic diversity found in this study are relevant to facilitate searching for unrelated matched donor and provide a healthy control population from our region that should be useful in the future disease association study. © 2013 American Society for Histocompatibility and Immunogenetics.

Background: Promoter hypermethylation of tumor suppressor genes presents promising markers for lung cancer diagnosis and prognosis. The purpose of this study was to determine the association between the promoter hypermethylation of multiple genes and 5‑year survival rate in patients with Non‑small cell lung cancer (NSCLC). Materials and Methods: Primary tumor samples (n = 65), corresponding nonmalignant lung tissues (n = 65), and circulating blood were obtained from NSCLC patients who underwent curative surgery. Promoter methylation status in seven genes (RASSF1A, CDH13, MGMT, ESR1, DAPK, SOX1, and HOXA9) was quantified by using bisulfite pyrosequencing. Five‑year survival data were obtained by a clinician. Cox proportional hazards models were used to analyze the associations between gene methylation status and overall patient survival. Results: The 5‑year survival of the patients with SOX1 aberrant tumor methylation was found to be statistically significantly shorter than for those patients without aberrant tumor methylation (P = 0.01). This effect was independent of TNM stage. No significant survival differences were associated with aberrant methylation in other genes tested in either of the two tissue types. Conclusion: Our study shows that SOX1 promoter hypermethylation in NSCLC tumors is significantly associated with inferior survival, showing promise as a useful prognostic biomarker in patients with NSCLC. © 2021 Journal of Cancer Research and Therapeutics.